Literature DB >> 29745474

Laparoscopic total gastrectomy for remnant gastric cancer: A single-institution experience.

Eisuke Booka1, Masaki Kaihara1, Koki Mihara1, Shin Nishiya1, Kan Handa1, Yasuhiro Ito1, Shintaro Shibutani1, Tomohisa Egawa1, Atsushi Nagashima1,2.   

Abstract

INTRODUCTION: The incidence of remnant gastric cancer is increasing because of past use of subtotal gastrectomy to treat peptic ulcer and increased survival rates after radical gastrectomy for gastric cancer. The feasibility and advantages of laparoscopic total gastrectomy (LTG) for remnant gastric cancer remain unclear. Therefore, we aimed to investigate the safety, feasibility, and clinical short-term outcomes of LTG for remnant gastric cancer.
METHODS: Patients who underwent completion total gastrectomy for remnant gastric cancer between April 2007 and October 2017 were divided into two groups: the open total gastrectomy (OTG) group and the LTG group. Clinicopathological data and short-term outcomes were analyzed.
RESULTS: A total of 31 remnant gastrectomies (23 OTG, 8 LTG) were performed. Blood loss was significantly lower in the LTG group than in the OTG group (135.5 vs 568.3 mL, P = 0.013). However, there was no significant difference in the operation time, days to food intake, or length of hospital stay between the two groups. Additionally, there was no significant difference in the postoperative complications, number of retrieved lymph nodes, or pathological findings. Two LTG patients (25.0%) required conversion to open surgery. There was no mortality in either group.
CONCLUSIONS: LTG for remnant gastric cancer can be a safe treatment option and may have an advantage of less blood loss than OTG.
© 2018 Japan Society for Endoscopic Surgery, Asia Endosurgery Task Force and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Gastric cancer; laparoscopic gastrectomy; remnant gastric cancer

Mesh:

Year:  2018        PMID: 29745474     DOI: 10.1111/ases.12495

Source DB:  PubMed          Journal:  Asian J Endosc Surg        ISSN: 1758-5902


  7 in total

1.  Laparoscopic Total Gastrectomy for Remnant Gastric Cancer: A Single-institution Experience and Systematic Literature Review.

Authors:  Mitsuhiko Ota; Masahiko Ikebe; Yuki Shin; Masaki Kagawa; Yohei Mano; Tomonori Nakanoko; Yuichiro Nakashima; Hideo Uehara; Masahiko Sugiyama; Tomohiro Iguchi; Keishi Sugimachi; Manabu Yamamoto; Masaru Morita; Yasushi Toh
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Laparoscopic gastrectomy in remnant gastric cancer.

Authors:  Egemen Çiçek; Akile Zengin; Örgün Güneş; Fatih Sümer; Cüneyt Kayaalp
Journal:  Turk J Surg       Date:  2021-03-22

3.  Remnant gastric cancer: An ordinary primary adenocarcinoma or a tumor with its own pattern?

Authors:  Marcus Fernando Kodama Pertille Ramos; Marina Alessandra Pereira; Andre Roncon Dias; Anna Carolina Batista Dantas; Daniel Jose Szor; Ulysses Ribeiro; Bruno Zilberstein; Ivan Cecconello
Journal:  World J Gastrointest Surg       Date:  2021-04-27

4.  Robotic total gastrectomy for carcinoma in the remnant stomach: a comparison with laparoscopic total gastrectomy.

Authors:  Zheng-Yan Li; Jia-Jia Liu; Pei-Wu Yu; Yong-Liang Zhao; Yan Shi; Zi-Yan Luo; Bin Wu; Jun-Jie Wang; Feng Qian
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-07-19

5.  Postoperative Complications and Their Risk Factors of Completion Total Gastrectomy for Remnant Gastric Cancer Following an Initial Gastrectomy for Cancer.

Authors:  Sin Hye Park; Sang Soo Eom; Bang Wool Eom; Hong Man Yoon; Young-Woo Kim; Keun Won Ryu
Journal:  J Gastric Cancer       Date:  2022-07       Impact factor: 3.197

6.  Current controversies in treating remnant gastric cancer: Are minimally invasive approaches feasible?

Authors:  Fu-Hai Ma; Hao Liu; Shuai Ma; Yang Li; Yan-Tao Tian
Journal:  World J Clin Cases       Date:  2019-11-06       Impact factor: 1.337

7.  Clinicopathologic features of remnant gastric cancer after curative distal gastrectomy according to previous reconstruction method: a retrospective cohort study.

Authors:  Yong-Eun Park; Sang-Woon Kim
Journal:  World J Surg Oncol       Date:  2019-11-30       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.